Nutritional Intervention for Age-related Muscular Function and Strength Losses-Study 2

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (544 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-02-04. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: factorial (lowers risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectstype diabetesageuseweeks since
  Phrases that lowered it: asthmabloodkgparticipate into participate
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 7.7% (lowers risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports marked serious: 63.1% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 21813 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area
• Minimum age: 60 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Nutritional Intervention for Age-related Muscular Function and Strength Losses NCT00874575 · started 2008 · scored riskier than 7% of active trials completed
• Zurich Disability Prevention Trial NCT01017354 · started 2010 · scored riskier than 26% of active trials completed
• Calcitriol, Physical Activity, and Bone Health in Cancer Survivors NCT00904033 · started 2008 · scored riskier than 58% of active trials completed
• Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons NCT04286529 · started 2020 · scored riskier than 14% of active trials terminated
• Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery NCT01138475 · started 2010 · scored riskier than 8% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.